Lorenzon D, Mazzucato M, Abbruzzese L, Cilli M, De Angeli S, Degan M, Mambrini G, Piccardi F, Rupolo M, Michieli M, De Marco L, Gattei V, Astori G
Clinical and Experimental Haematology Research Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, PN, Italy.
Vox Sang. 2008 May;94(4):342-50. doi: 10.1111/j.1423-0410.2008.01038.x. Epub 2008 Feb 14.
Ex vivo peripheral blood progenitor cell (PBPC) expansion has been proposed as a strategy to increase the number of haematopoietic progenitors available for cell transplantation. We have expanded CD34+ cells from PBPCs obtained from four patients with haematological malignancies and one patient with an Ewing's sarcoma.
Cells were expanded in the Dideco 'Pluricell system'. After 12 days in culture, we evaluated cell phenotype, total nucleated cells, CD34+ fold increase, cell apoptosis and colony assay of expanded cells. Cell engraftment has been evaluated by transplanting two groups of irradiated non-obese diabetic/severe combined immunodeficient (NOD-SCID) mice with expanded and non-expanded cell populations.
Total nucleated cells and CD34+ cells increased 59.5 and 4.0 times, respectively. The expanded cells were mainly constituted of myeloid and megakaryocytic cells. A significant increase in the number of colony-forming unit-granulocyte macrophage (CFU-GM) was observed in the CFU assay. Ten mice transplanted with expanded cells showed a best overall survival (80%) compared to 10 mice transplanted with non-expanded cells (20%). Human CD45+ cells were detected by flow cytometry and polymerase chain reaction in bone marrow and spleen of transplanted animals. The relative low engraftment level obtained with the expanded cells suggests a loss of SCID repopulating cells maybe due to cell differentiation during expansion.
We have demonstrated the feasibility of the ex vivo expansion of mobilized PBPCs from cancer patients, evidencing a clonal expansion of CFUs and the ability of the expanded cells to engraft the bone marrow and spleen of immunosuppressed mice. The differentiation of the CD34+ stem cell compartment could be further minimized by ameliorating the expansion conditions.
体外扩增外周血祖细胞(PBPC)已被提议作为一种增加可用于细胞移植的造血祖细胞数量的策略。我们从4例血液系统恶性肿瘤患者和1例尤因肉瘤患者获取的PBPC中扩增了CD34⁺细胞。
细胞在Dideco“Pluricell系统”中进行扩增。培养12天后,我们评估了细胞表型、总核细胞、CD34⁺细胞增加倍数、细胞凋亡以及扩增细胞的集落分析。通过将两组经辐照的非肥胖糖尿病/严重联合免疫缺陷(NOD-SCID)小鼠分别移植扩增和未扩增的细胞群体来评估细胞植入情况。
总核细胞和CD34⁺细胞分别增加了59.5倍和4.0倍。扩增后的细胞主要由髓系细胞和巨核细胞组成。在集落分析中观察到集落形成单位-粒细胞巨噬细胞(CFU-GM)数量显著增加。与移植未扩增细胞的10只小鼠(20%)相比,移植扩增细胞的10只小鼠总体生存率更高(80%)。通过流式细胞术和聚合酶链反应在移植动物的骨髓和脾脏中检测到人类CD45⁺细胞。扩增细胞获得的相对较低植入水平表明,可能由于扩增过程中的细胞分化导致严重联合免疫缺陷(SCID)重建细胞丢失。
我们已经证明了从癌症患者动员的PBPC进行体外扩增的可行性,证明了CFU的克隆扩增以及扩增细胞植入免疫抑制小鼠骨髓和脾脏的能力。通过改善扩增条件,CD34⁺干细胞区室的分化可进一步最小化。